Discover
Pharma and BioTech Daily
Pharma and BioTech Daily
Author: Pharma and BioTech News
Subscribed: 141Played: 2,649Subscribe
Share
© 2026 Pharma and BioTech Daily
Description
Pharma & Biotech Daily is a short, AI-generated, human-supervised briefing on what’s important in pharma and biotech.
Each weekday we condense key news on pipelines, deals, regulation and strategy into a quick audio update for people who build, run and invest in life sciences.
Produced by OWITH.ai, a boutique AI & data studio.
Sponsor the show: https://sponsor.owith.ai
380 Episodes
Reverse
The FDA approved Regeneron's Livsayis, the first RNA interference drug for an autoimmune disease, and a US national security commission warned that China's five year plan could let it corner biopharma. We also cover reports that Sanofi is weighing a takeover of Insmed and Arcera's licensing deal for Innogen's GLP-1 drug.
Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Friday, November 20.
Today, Regeneron wins approval for its first RNA i...
Pfizer licenses three in vivo CAR T programs from China's Starna Therapeutics in a deal worth up to 2.6 billion dollars, and Merck ends its nemtabrutinib program after a Phase 3 benefit risk review. Also: the FDA's published rejection letter for Summit's ivonescimab, Bristol Myers Squibb's Cobenfy data in Alzheimer's psychosis, and Biogen's protein degrader pact with Trimtech.
Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Thursday, Novem...
GSK wins accelerated FDA approval for Nelkarmi in previously treated ALK positive lung cancer, and Isomorphic Labs raises a record 5 billion dollar Series C. Also: Lilly's oncology pact with Stipple Bio worth up to 5.9 billion dollars and a split Phase 3 result for AriBio's AR1001 in Alzheimer's disease.
Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Wednesday, November 18.
Today, GSK wins an early FDA nod for its new lung cancer drug, a...
Johnson & Johnson pays $2.2 billion upfront for Ollin Biosciences and its Vabysmo challenger OLN324, and the FDA approves Genentech's Wilserdly (giredestrant) for ESR1 mutated breast cancer. Also: Helus Pharma's Phase 3 depression win, Lilly's purchase of Calytrix Bio, Seawolf's Sanofi pact and Novartis' ADC deal with OBI Pharma.
Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Tuesday, November 17.
Today, Johnson and Johnson pays two ...
The FDA has rejected Summit and Akeso's lung cancer antibody ivonescimab over a missing overall survival win, while Europe's CHMP backed AstraZeneca's blood pressure drug Baxfendy and two China origin lung cancer medicines. We also cover Zevra's upheld refusal in Europe and Cellectis' deep job cuts as it pivots to in vivo gene editing.
Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Monday, November 16.
Since Friday, the FDA has turned do...



